An observational study in Age-Related (Dry) Macular Degeneration, Age-Related Macular Degeneration (AMD) and AMD Population - Intermediate or Advanced AMD, sponsored by IRCCS San Raffaele. Not yet recruiting. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Age-related macular degeneration (AMD) is the major cause of legal blindness in developed countries. Intermediate AMD represents the most frequent stage. However, it often evolves towards complicated stages, namely neovascular AMD or geographic atrophy (GA). Despite the available treatments, the visual outcome is highly heterogeneous. The scientific interest is growing regarding the assessment of neuroretinal changes in AMD. Although AMD is mainly considered an outer retinal disease, recent evidence suggests a major involvement of retinal glia and neurons, i.e. an involvement of the inner retina. This damage may remarkably affect the morphological and functional AMD outcome, subverting retinal signal transmission cascade and more clearly explaining the outcome of the disease. The main goal of this study is to perform a multidisciplinary, multicenter, both prospective and retrospective evaluation of neuroretinal degeneration in different AMD stages in preclinical and clinical models.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
This study's planned enrollment of 160 is above the median of 71 across 127 observational studies indexed under Macular Edema.
Browse Macular Edema studies →IRCCS San Raffaele is the lead sponsor of 454 studies on the registry; 235 are open to participants now.
Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients affected by intermediate, wet and dry (geographic atrophy) age-related macular degeneration (AMD) and healthy age- and gender-matched controls
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients affected by intermediate, wet and dry atrophic AMD
Healthy age- and gender-matched control
Neuroretinal degeneration quantitative metrics
Quantitative multimodal retinal imaging metrics associated with inner retinal changes and neuroretinal degeneration
Time frame: From January 2027 to January 2030
Imaging metrics of neuroretinal changes
Multimodal retinal imaging metrics associated with inner retinal changes and neuroretinal degeneration
Time frame: From January 2027 to January 2030
MicroRNA profiles associated with AMD stages
MicroRNAs different profiles associated with AMD stages, risk of progression and neuroretinal degeneration.
Time frame: From January 2027 to January 2030
No study locations are listed for this record.
Plan to share: Yes — Scientific publications and international conferences.
Start is estimated for Jan 2027; primary completion for Jun 2029, 29 months later.
Of 44 observational studies under Macular Edema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 29 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.